Focus on Insulin Resistance in Type 2 Diabetes: Therapeutic Implications

The Diabetes Educator

Volumn 24, Issue 2, 1998, Pages 188-193

  Reusch, Jane E B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DIET; EXERCISE; HUMAN; INSULIN RESISTANCE; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SECRETION;

COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; RISK FACTORS;

EID: 0032018107     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572179802400209     Document Type: Article

References (35)

1. Rossetti L., Giaccari A., DeFronzo RA Glucose toxicity. Diabetes Care. 1990 :13:610-30.
2. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md : National institutes of Health. 1995; NIH publication no. 95-1468.
3. Bailey CJ, Turner RC Drug therapy: metformin. N Engl J Med. 1996 ;334: 574-79.
4. Nolan JJ, Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Mcd. 1994 ;331:1188-93.
5. Kellerer M., Kroder G., Tippmer S., et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-I fibroblasts. Diabetes. 1994:43:447-53.
6. Hollander PA New oral agents for type II diabetes: taking a more aggressive approach to therapy. Diabetes. 1995:90:110-26.
7. Bohannon N, Jack DB Type II diabetes: how to use the new oral medications. Geriatrics. 1996;51:33-37.
8. White MF, Cahn CR The insulin signaling system. Bio Chem. 1994 ;269: 1-4.
9. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992; 15:318-68.
10. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care. 1992;15:430-41.
11. Leahy JL, Bonner-Weir S., Weir GC P cell dysfunction induced by chronic hyperglycemia. Diabetes Care. 1992,15:442-55.
12. Henry RR, Wallace P., Olefsky JM Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes. 1986 :35:990-98.
13. Gumbiner B., Polonsky KS, Beitz WF, et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70:159d-1602.
14. Baron AD Insulin in the vasculature: old actors, new roles. J Invest Med. 1996;44:406-28.
15. Garvey WT Glucose transport and NIDDM. Diabetes Care. 1992;15: 396-417.
16. Beck-Nielsen H., Vaag A., Damsbo P., et al. Insulin resistance in skeletal muscles in patients with NIDDM. Diabetes Care. 1992 ;15:418-29.
17. Schneider SH Council on Exercise. Technical review: exercise and NIDDM. Diabetes Care. 1990:13:785-R9.
18. Blake GH Control of type II diabetes: reaping the rewards of exercise and weight loss. Postgrad Med. 1992;92:129-37.
19. Horton E. Exercise and physical training. Effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev. 1986;2:1-17.
20. Williams B. Insulin resistance: the shape of things to come. Lancet. 1994 ; 344:521-24.
21. Weir GC Which comes first in non-insulin-dependent diabetes mellitus: insulin resistance or beta cell failure? Both come first. JAMA. 1995;273: 1878-79.
22. Keen H. Insulin resistance and the prevention of diabetes mellitus. N Engl J Med. 1994;331:1226-27.
23. Reaven GM Syndrome X. Clin Diabetes. 1994; Mar/Apr: 32-36.
24. Yki-Jirvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet. 1994;343:91-95.
25. Stem MP, Mitchell BD, Haffner SM, Hazuda HP Does glycemic control of type 11 diabetes suffice to control diabetic dyslipidemia? Diabetes Care. 1992; 15:638-44.
26. Hughes TA, Gwynne JT, Switzwer BR, Herbst C., White G. Effects ofcaloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med. 1984 ;77:7-17.
27. Ogihara T., Rakugi H. Ikegami H, Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995 ;8:316-20.
28. Regensteiner JG, Sippel J., McFarling ET, Wolfel EE, Hiatt WR Effects on non-insulin-dependent diabetes mellitus of oxygen consumption during treadmill exercise. Med Sci Sports Exerc. 1995;27:875-81.
29. Glasgow RE, Toobert DJ, Hampson SE, Brown JE, Lewinsohn PM, Donnelly J. Improving self-care among older patients with type 11 diabetes: the “Sixty Something …” Study. Patient Educ Couns. 1992 ;19:61-74.
30. Polonsky KS, Sturis J., Bell GI Non-insulin-dependent diabetes mellitus — a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777-83.
31. Pimenta W. Korytkowski M, Mitrakou A., et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855-61.
32. Nerenz DR, Repasky DP, Whitehouse FW, Kahkonen DM Ongoing assessment of health status in patients with diabetes mellitus. Medical Care. 1992,30:MS112-23.
33. Henry RR, Gumbiner B., Ditzler T., Wallace P., Lyon R., Glauber HS Intensive conventional insulin therapy for type II diabetes. Diabetes Care. 1993;16:21-31.
34. Franz MJ, Horton ES Sr, Bantle JP, et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care. 1994;17: 490-518.
35. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 1994; 17:519-22.